1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014’, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 6
Therapeutics Development 7
Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview 7
Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis 8
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies 9
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 10
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies 13
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 14
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development 15
Galapagos NV 15
Arsanis Biosciences GmbH 16
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Molecule Type 22
Drug Profiles 24
RUT-5860 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
GLPG-1492 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
acALY-18 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
ASN-100 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
siderocillin - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
LTA-001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Recent Pipeline Updates 32
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects 34
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products 35
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Product Development Milestones 36
Featured News and Press Releases 36
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 36
Jan 07, 2013: New compound overcomes drug-resistant Staph infection in mice 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H2 2014 7
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Galapagos NV, H2 2014 15
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Arsanis Biosciences GmbH, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Molecule Type, H2 2014 23
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H2 2014 32
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects, H2 2014 34
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products, H2 2014 35

List of Figures

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H2 2014 7
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Target, H2 2014 18
Number of Products by Stage and Top 10 Target, H2 2014 19
Number of Products by Top 10 Mechanism of Action, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 21
Number of Products by Top 10 Molecule Type, H2 2014 22
Number of Products by Stage and Top 10 Molecule Type, H2 2014 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The global anti-infective agents market is expected to reach over USD 111.4 billion by 2024 according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as HIV, ...

Global Feed Antibiotics Market

October 2016 $ 4250

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.